Brought to you by 
Aralez signs LOI to divest Canadian spec pharma operations to Nuvo; later signs definitive agreement
28 May 2019
Executive Summary
Nuvo Pharmaceuticals Inc. signed a non-binding letter of intent (LOI) under a stalking-horse bid process to acquire Aralez Pharmaceuticals Inc.'s Canadian specialty pharmaceutical business, formerly known as Tribute Pharmaceuticals Canada Inc., along with associated personnel and infrastructure. Aralez plans to negotiate with Nuvo to execute a definitive agreement by August 19, 2018.
Deal Industry
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Aralez signs LOI to divest Canadian spec pharma operations to Nuvo; later signs definitive agreement
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice